Near-identical protein on SARS and COVID-19 could be targeted by FDA-approved drugs
According to researchers, drugs that target envelope protein E on the SARS viral membrane could also be used to target a similar protein on COVID-19.
List view / Grid view
According to researchers, drugs that target envelope protein E on the SARS viral membrane could also be used to target a similar protein on COVID-19.
The third phase of the ENCODE project has been released, with new information on genes and their potential regulators in their respective genomes.
A new technology named OligoFISSEQ has been created which can image and three-dimensionally map the genomes in hundreds of cells at the same time.
Researchers have created a new method of potentially treating herpes virus, by targeting the physical properties of the viral genome.
Researchers have modified the COVID-19 Spike protein for use in vaccines, which produces up to 10 times more protein than that of an earlier synthetic versions.
A new CRISPR technology has been created to understand mutations based on cytosine to guanine base changes and minimise unintended "off-target" mutations.
Researchers suggest the SRPX2 protein, which inhibits complement system-dependent synapse removal could be a target for novel Alzheimer’s and schizophrenia therapies.
A new study reveals that the Toxoplasma gondii parasite acts through the IRE1 protein to cause infected cells to migrate through the body, spreading the parasite.
Researchers reveal a combination of PD1 immunotherapy and BMI1 protein inhibition eliminated cancer stem cells and prevented cancer recurrence in a mouse model.
The vaccine candidate repRNA-CoV2S elicited both antibody and T cell responses after just two injections in mice and macaques.
Which immune cells contribute towards immune-induced neurodegeneration and how could this knowledge enable conditions such Alzheimer’s and multiple sclerosis to be treated?
As more of the small devices in the lab become connected, more laboratory workflows will be observable, and variability will be better understood.
Researchers show that the mutated huntingtin protein associated with Huntington’s disrupts the transport of essential proteins within the neuron, potentially highlighting an early cause of the disease.
A study of the SARS-CoV-2 nonstructural protein 1 (Nsp1) showed it can supress translation and inhibit anti-viral defence mechanisms, making it a potential target for drugs.
The novel CRISPR-CasΦ enzyme, isolated from bacteriophages, can target a wider range of genetic sequences, say the researchers.